306 related articles for article (PubMed ID: 30790684)
1. STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity.
Pei J; Zhang Y; Luo Q; Zheng W; Li W; Zeng X; Li Q; Quan J
Cancer Lett; 2019 May; 450():110-122. PubMed ID: 30790684
[TBL] [Abstract][Full Text] [Related]
2. cGAS-STING signaling in cancer immunity and immunotherapy.
Du H; Xu T; Cui M
Biomed Pharmacother; 2021 Jan; 133():110972. PubMed ID: 33254021
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy and cGAS/STING signaling: Impact on MDSCs in the tumor microenvironment.
Kho VM; Mekers VE; Span PN; Bussink J; Adema GJ
Cell Immunol; 2021 Apr; 362():104298. PubMed ID: 33592541
[TBL] [Abstract][Full Text] [Related]
4. Feedback activation of CD73-Adenosine axis attenuates the antitumor immunity of STING pathway.
Fu N; Zhang Z; Quan J
Biochem Biophys Res Commun; 2024 May; 708():149814. PubMed ID: 38531218
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy.
Zheng J; Mo J; Zhu T; Zhuo W; Yi Y; Hu S; Yin J; Zhang W; Zhou H; Liu Z
Mol Cancer; 2020 Aug; 19(1):133. PubMed ID: 32854711
[TBL] [Abstract][Full Text] [Related]
6. DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients.
Vasiyani H; Mane M; Rana K; Shinde A; Roy M; Singh J; Gohel D; Currim F; Srivastava R; Singh R
Apoptosis; 2022 Dec; 27(11-12):961-978. PubMed ID: 36018392
[TBL] [Abstract][Full Text] [Related]
7. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
Corrales L; Gajewski TF
Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
[TBL] [Abstract][Full Text] [Related]
9. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion.
Zhang CX; Ye SB; Ni JJ; Cai TT; Liu YN; Huang DJ; Mai HQ; Chen QY; He J; Zhang XS; Zeng YX; Li J; Cui J
Cell Death Differ; 2019 Nov; 26(11):2314-2328. PubMed ID: 30816302
[TBL] [Abstract][Full Text] [Related]
10. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
[TBL] [Abstract][Full Text] [Related]
11. cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development.
Ng KW; Marshall EA; Bell JC; Lam WL
Trends Immunol; 2018 Jan; 39(1):44-54. PubMed ID: 28830732
[TBL] [Abstract][Full Text] [Related]
12. Development of small molecule inhibitors/agonists targeting STING for disease.
Liu K; Lan Y; Li X; Li M; Cui L; Luo H; Luo L
Biomed Pharmacother; 2020 Dec; 132():110945. PubMed ID: 33254439
[TBL] [Abstract][Full Text] [Related]
13. Insight into the dichotomous regulation of STING activation in immunotherapy.
Hu Z; Yang Y; Fang L; Zhou J; Zhang H
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
[TBL] [Abstract][Full Text] [Related]
14. cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response.
Bose D
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156566
[TBL] [Abstract][Full Text] [Related]
15. STING Activation and its Application in Immuno-Oncology.
Lian Y; Duffy KJ; Yang J
Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
[TBL] [Abstract][Full Text] [Related]
16. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.
Ohkuri T; Ghosh A; Kosaka A; Zhu J; Ikeura M; David M; Watkins SC; Sarkar SN; Okada H
Cancer Immunol Res; 2014 Dec; 2(12):1199-208. PubMed ID: 25300859
[TBL] [Abstract][Full Text] [Related]
17. Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches.
Khoo LT; Chen LY
EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30446584
[TBL] [Abstract][Full Text] [Related]
18. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade.
Wang M; Huang Y; Chen M; Wang W; Wu F; Zhong T; Chen X; Wang F; Li Y; Yu J; Wu M; Chen D
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37620043
[TBL] [Abstract][Full Text] [Related]
20. cGAS-STING, an important pathway in cancer immunotherapy.
Jiang M; Chen P; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; Ye L; He Y; Zhou C
J Hematol Oncol; 2020 Jun; 13(1):81. PubMed ID: 32571374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
